2019 American Transplant Congress
The Need for Diabetic Medications after Pancreas Transplantation
Mount Sinai Hospital, New York, NY
*Purpose: Patients with diabetes mellitus can experience microvascular complications resulting in end organ damage ultimately necessitating pancreatic transplantation. While there is well documented improvement in…2019 American Transplant Congress
FK506 Influence Glucose Metabolism by Short Chain Fatty Acid
*Purpose: FK506 is one of the most common immunosuppressant drugs in organ transplantation, which have been demonstrated to cause glucose metabolism disorder and alterd the…2019 American Transplant Congress
Impact of Steroid-Free Protocol on Incidence of Posttransplantation Diabetes Mellitus: A Prospective, Randomized, Multicenter, Open-Label, Controlled Trial in Renal Transplant Recipients
*Purpose: Comparison of two immunosuppressive protocols, steroid-free with antithymocyte globulin (ATG) induction, and steroid containing with basiliximab induction, regarding the incidence of PTDM, one year…2019 American Transplant Congress
Efficacy and Safety with Empagliflozin in Renal Transplant Recipients with Post-Transplant Diabetes Mellitus
*Purpose: Post-transplant diabetes mellitus (PTDM) is a highly prevalent condition following renal transplantation, associated with increased risk of cardiovascular disease and impaired patient survival. Sodium-glucose…2019 American Transplant Congress
Belatacept Based Simultaneous Calcineurin Inhibitor Avoidance/Early Corticosteroid Withdrawal is Associated with Low New Onset Diabetes Risk
*Purpose: Calcineurin inhibitor (CNI) and/or corticosteroid (CCS) therapy are associated with significant risk of new onset diabetes after transplantation (NODAT). An important consideration for simultaneous…2019 American Transplant Congress
Comparison of Two Glucagon-Like-Peptide-1 Analogs (GLP -1) Dulaglutide vs Liraglutide for the Management of Diabetes in Solid Organ Transplant (SOT)
Ohio State University, Columbus, OH
*Purpose: Poorly controlled Type-2 diabetes is an important contributor to graft dysfunction, and cardiovascular morbidity in the SOT. GLP-1-analog has been widely used in the…2019 American Transplant Congress
TDCA/Valine Reverse Obesity and Ameliorate Alloimmune Responses through a Decreased Hypothalamic Expression of MCH
1Brigham and Women's Hospital, Boston, AL, 2Beth Israel Deaconess Medical Center, Boston, AL
*Purpose: Obesity is associated with low grade inflammation and bariatric surgery is the only effective treatment in reducing excess weight both pre- and post-transplant.*Methods: Here,…2019 American Transplant Congress
Association Of Lymphocyte-depleting Antibody And Steroids Induction With The Risk And Outcomes Of Post-transplant Diabetes: Analysis Of Deceased-donor Kidney Transplants
*Purpose: We aimed to determine the risk and outcomes of post-transplant diabetes(PTDM) associated with combined lymphocyte-depleting antibody (LDA) [anti-thymocyte globulin (ATG) or alemtuzumab (ALM)] and…2019 American Transplant Congress
Impact of Hepatitis C Viremia on Post-Transplant Diabetes Mellitus Development in Liver Transplant Recipients
*Purpose: Compare incidence of post-transplant diabetes mellitus (PTDM) in hepatitis C virus (HCV) patients with and without viremia at the time of orthotopic liver transplantation…2019 American Transplant Congress
Pharmacist-Led Management of Post-Transplant Hyperglycemia Reduces Hospitalizations
*Purpose: Renal transplant recipients (RTRs) are at risk of developing post-transplant hyperglycemia (PTHG), defined as blood glucose > 180 mg/dL within the first 45 days…
American Transplant Congress abstracts